Literature DB >> 34838826

M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942.

Ke Wei1, Zijian Ma2, Fengming Yang3, Xin Zhao4, Wei Jiang5, Chunfeng Pan1, Zhihua Li1, Xianglong Pan1, Zhicheng He1, Jing Xu1, Weibing Wu6, Yang Xia7, Liang Chen8.   

Abstract

Tumor-associated macrophages (TAMs) are the major components of the tumor microenvironment that contribute to metastasis in lung adenocarcinoma (LUAD). The potential of TAM-derived exosomes for biomarker discovery in tumor initiation and progression has been recently reported. However, studies on macrophage-derived exosomes in LUAD remain limited. We investigated the role of M2 macrophage-derived exosomes in LUAD both in vivo and in vitro and its underlying mechanism. We showed that the infiltration of M2 macrophages was positively correlated with LUAD metastasis. M2 macrophage-derived exosomes could be taken up by LUAD cells to promote cell migration, invasion, and angiogenesis. Furthermore, miR-942 could be packaged into exosomes secreted by M2 macrophages. Mechanistically, exosomal miR-942 regulates FOXO1 protein expression by binding to the 3'-UTR region of FOXO1 and further alleviates β-catenin inhibition in LUAD cells. Collectively, we demonstrated that M2 macrophage-derived miRNA-containing exosomes promote LUAD cell invasion and migration and facilitate angiogenesis, thereby providing a new therapeutic target for metastatic LUAD.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; FOXO1; Metastasis; TAMs; miRNA

Mesh:

Substances:

Year:  2021        PMID: 34838826     DOI: 10.1016/j.canlet.2021.10.045

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  The FOXO family of transcription factors: key molecular players in gastric cancer.

Authors:  Ying Liu; Xiang Ao; Yi Jia; Xiaoge Li; Yu Wang; Jianxun Wang
Journal:  J Mol Med (Berl)       Date:  2022-06-10       Impact factor: 5.606

Review 2.  Macrophage-Derived Extracellular Vesicles: A Promising Tool for Personalized Cancer Therapy.

Authors:  Antonella Barone; Nicola d'Avanzo; Maria Chiara Cristiano; Donatella Paolino; Massimo Fresta
Journal:  Biomedicines       Date:  2022-05-27

Review 3.  Macrophage-Derived Small Extracellular Vesicles in Multiple Diseases: Biogenesis, Function, and Therapeutic Applications.

Authors:  Jingyao Ye; Xuehong Liu
Journal:  Front Cell Dev Biol       Date:  2022-06-27

4.  Exosomes derived from reparative M2-like macrophages prevent bone loss in murine periodontitis models via IL-10 mRNA.

Authors:  Xutao Chen; Zhuo Wan; Liu Yang; Shuang Song; Zhaoyue Fu; Kang Tang; Lihua Chen; Yingliang Song
Journal:  J Nanobiotechnology       Date:  2022-03-05       Impact factor: 10.435

Review 5.  Emerging function and clinical significance of extracellular vesicle noncoding RNAs in lung cancer.

Authors:  Chan Shan; Yan Liang; Hongjing Cai; Fei Wang; Xinzhe Chen; Qikun Yin; Kun Wang; Yin Wang
Journal:  Mol Ther Oncolytics       Date:  2022-02-20       Impact factor: 7.200

Review 6.  MicroRNA-31: a pivotal oncogenic factor in oral squamous cell carcinoma.

Authors:  Xiaojiao Lin; Weizhou Wu; Yukang Ying; Jun Luo; Xuhui Xu; Linxia Zheng; Weili Wu; Suqing Yang; Shankun Zhao
Journal:  Cell Death Discov       Date:  2022-03-29

Review 7.  Exosomes as Crucial Players in Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Yue Fei; Qi Liu; Na Peng; Guocan Yang; Ziwei Shen; Pan Hong; Shengjun Wang; Ke Rui; Dawei Cui
Journal:  J Immunol Res       Date:  2022-07-20       Impact factor: 4.493

Review 8.  Non-coding RNAs in lung cancer: emerging regulators of angiogenesis.

Authors:  Yajie Liao; Xudong Wu; Mengyu Wu; Yuan Fang; Jie Li; Weiqiang Tang
Journal:  J Transl Med       Date:  2022-08-02       Impact factor: 8.440

9.  Tumor-associated macrophage-derived exosomes promote EGFR-TKI resistance in non-small cell lung cancer by regulating the AKT, ERK1/2 and STAT3 signaling pathways.

Authors:  Shiyang Yuan; Wenjun Chen; Jian Yang; Yuanhai Zheng; Wen Ye; Hui Xie; Lie Dong; Junping Xie
Journal:  Oncol Lett       Date:  2022-08-24       Impact factor: 3.111

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.